BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 33971042)

  • 1. Early Discrimination Between Tumor-Induced Rickets/Osteomalacia and X-Linked Hypophosphatemia in Chinese Children and Adolescents: A Retrospective Case-Control Study.
    Jiajue R; Ni X; Jin C; Huo L; Wu H; Liu Y; Jin J; Yu W; Lv W; Zhou L; Xia Y; Chi Y; Cui L; Pang Q; Li X; Jiang Y; Wang O; Li M; Xing X; Meng X; Xia W
    J Bone Miner Res; 2021 Sep; 36(9):1739-1748. PubMed ID: 33971042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone Volumetric Density, Microarchitecture, and Estimated Bone Strength in Tumor-Induced Rickets/Osteomalacia
    Jiajue R; Ni X; Jin C; Yu W; Huo L; Wu H; Liu Y; Jin J; Lv W; Zhou L; Xia Y; Chi Y; Cui L; Pang Q; Li X; Jiang Y; Wang O; Li M; Xing X; Meng X; Xia W
    Front Endocrinol (Lausanne); 2022; 13():883981. PubMed ID: 35769089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. X-Linked Hypophosphatemia: Uniquely Mild Disease Associated With PHEX 3'-UTR Mutation c.*231A>G (A Retrospective Case-Control Study).
    Smith PS; Gottesman GS; Zhang F; Cook F; Ramirez B; Wenkert D; Wollberg V; Huskey M; Mumm S; Whyte MP
    J Bone Miner Res; 2020 May; 35(5):920-931. PubMed ID: 31910300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries.
    Al Juraibah F; Al Amiri E; Al Dubayee M; Al Jubeh J; Al Kandari H; Al Sagheir A; Al Shaikh A; Beshyah SA; Deeb A; Habeb A; Mustafa M; Zidan H; Mughal MZ
    Arch Osteoporos; 2021 Mar; 16(1):52. PubMed ID: 33660084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23.
    Ito N; Kubota T; Kitanaka S; Fujiwara I; Adachi M; Takeuchi Y; Yamagami H; Kimura T; Shinoda T; Minagawa M; Okazaki R; Ozono K; Seino Y; Fukumoto S
    J Bone Miner Metab; 2021 Nov; 39(6):1066-1075. PubMed ID: 34255195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders.
    Ramos P; Larson B; Ashrafzadeh-Kian S; Ito N; Kato H; Bornhorst JA; Algeciras-Schimnich A
    Endocr Pract; 2023 Mar; 29(3):193-198. PubMed ID: 36627024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia.
    Imanishi Y; Ito N; Rhee Y; Takeuchi Y; Shin CS; Takahashi Y; Onuma H; Kojima M; Kanematsu M; Kanda H; Seino Y; Fukumoto S
    J Bone Miner Res; 2021 Feb; 36(2):262-270. PubMed ID: 32967046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
    Athonvarangkul D; Insogna KL
    Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of FGF23 Levels for the Diagnosis of FGF23-Mediated Hypophosphatemia.
    Hartley IR; Gafni RI; Roszko KL; Brown SM; de Castro LF; Saikali A; Ferreira CR; Gahl WA; Pacak K; Blau JE; Boyce AM; Salusky IB; Collins MT; Florenzano P
    J Bone Miner Res; 2022 Nov; 37(11):2174-2185. PubMed ID: 36093861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
    Kinoshita Y; Fukumoto S
    Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
    Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
    Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of bone markers in hypophosphatemic rickets/osteomalacia.
    Nagata Y; Imanishi Y; Ishii A; Kurajoh M; Motoyama K; Morioka T; Naka H; Mori K; Miki T; Emoto M; Inaba M
    Endocrine; 2011 Oct; 40(2):315-7. PubMed ID: 21822687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
    Fukumoto S
    J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium.
    Laurent MR; De Schepper J; Trouet D; Godefroid N; Boros E; Heinrichs C; Bravenboer B; Velkeniers B; Lammens J; Harvengt P; Cavalier E; Kaux JF; Lombet J; De Waele K; Verroken C; van Hoeck K; Mortier GR; Levtchenko E; Vande Walle J
    Front Endocrinol (Lausanne); 2021; 12():641543. PubMed ID: 33815294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low Levels of Serum Sclerostin in Adult Patients With Tumor-Induced Osteomalacia Compared With X-linked Hypophosphatemia.
    Ni X; Zhang Q; Li X; Pang Q; Gong Y; Wang O; Li M; Xing X; Jiang Y; Xia W
    J Clin Endocrinol Metab; 2022 Jan; 107(1):e361-e371. PubMed ID: 34363479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.].
    Kinoshita Y
    Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma intact fibroblast growth factor 23 level is a useful tool for diagnostic approach of renal hypophosphatemia.
    Giralt M; Chocron S; Ferrer R; Ariceta G
    Pediatr Nephrol; 2021 Apr; 36(4):1025-1028. PubMed ID: 33492457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGF23 and Hypophosphatemic Rickets/Osteomalacia.
    Takashi Y; Kawanami D; Fukumoto S
    Curr Osteoporos Rep; 2021 Dec; 19(6):669-675. PubMed ID: 34755323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment.
    Endo I; Fukumoto S; Ozono K; Namba N; Inoue D; Okazaki R; Yamauchi M; Sugimoto T; Minagawa M; Michigami T; Nagai M; Matsumoto T
    Endocr J; 2015; 62(9):811-6. PubMed ID: 26135520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of FGF23-related hypophosphatemic osteomalacia by alcohol consumption.
    Hidaka N; Kato H; Koga M; Katsura M; Oyama Y; Kinoshita Y; Fukumoto S; Makita N; Nangaku M; Ito N
    Bone Rep; 2021 Dec; 15():101144. PubMed ID: 34901334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.